DNLI - Denali Therapeutics Inc.
IEX Last Trade
21.56
0.160 0.742%
Share volume: 11,113
Last Updated: Thu 26 Dec 2024 08:30:11 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$21.40
0.16
0.75%
Fundamental analysis
11%
Profitability
8%
Dept financing
4%
Liquidity
75%
Performance
0%
Performance
5 Days
0.67%
1 Month
-15.24%
3 Months
-28.53%
6 Months
-4.91%
1 Year
-6.40%
2 Year
-21.65%
Key data
Stock price
$21.56
DAY RANGE
$20.54 - $21.48
52 WEEK RANGE
$15.25 - $33.33
52 WEEK CHANGE
-$4.69
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO: Ryan J. Watts
Region: US
Website: denalitherapeutics.com
Employees: 430
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: denalitherapeutics.com
Employees: 430
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Denali Therapeutics Inc. discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate product candidate. BIIB122/DNL151, a small molecule inhibitor, is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease.
Recent news